SPARKS, Nev., Sept. 13, 2004 (PRIMEZONE) -- NT Holding Corp. (OTCBB:NTHH), a publicly traded holding company, is pleased to announce that its subsidiary, PNC LABS, INC. has entered into a sales and distribution agreement with Preventive Nutrient, Inc. ("Preventive") to distribute its products which stimulate healthy glucose metabolism.
NT Holding Corp. President Alan Lew said, "We are excited in landing this opportunity to distribute science based and tested products, we hope to make an impact on the community as the number of people diagnosed with diabetes and suffering from obesity is staggering." He further stated that "Preventive has tested these products and its ability to lower the gluclose level in animals." He also mentioned, "In addition, PNC has commenced development of proprietary nutraceutical products to enhance our value." Said Dr. Moon Song, President of Preventive, "I am excited this strategic collaberation has formed and look forward to working with PNC Labs to enhance and grow its sales activities. I feel very positive about this first step in a meaningful business relationship." Mr. Lew also welcomed Dr. Song as the newest addition to the PNC Labs scientific advisory board.
About PNC LABS
PNC LABS, INC., a subsidiary of NT Holding Corp. is a nutritional supplements company serving the preventive and alternative healthcare segments, and looking to expand through an acquisition with organic growth strategy. The company is selectively evaluating niche companies in order to provide quality nutraceuticals to consumers. The company further plans to be fully integrated in manufacturing, distribution and marketing. The company says it is in discussions with several acquisition candidates. PNC LABS is targeting companies with less than $5 million in annual sales.
About Diabetes
Diabetes is a loose term that defines anyone who has a condition where they are unable to process glucose correctly, either from lack of enough insulin, or the inability for the body to use the stored glucose.
-- Increasing Population of Diabetes Patients In 1990, the percentage of US diabetic patient population was 4.9 % and 6.5 % in 1991. It was reported to be 7.3% in the year of 2000 and 2002 7.9%.(1)
The number of diabetic patients in the United State is estimated to reach 30 million by the year of 2005.
More than 33 % of the US populations older than age 60 are diabetic.
More than 67 % of US populations are either overweight or obese. According to the recent publication by Center for Disease Control, the incidence of diabetes increased about 50% and lifetime risk of developing diabetes for individuals born in 2000 are 32.8% for males and 38.5 % for females.
Currently, about 1 million Americans are type 1 (juvenile diabetes) and 17 millions are type 2 diabetes (adult onset diabetes)(2).
Advancing healthcare seeks a substantial increase in the longevity of people, and along with it, concerns about the quality of life. Diabetes as well as other health issues will only increase with time. Insulin and oral agents have blood glucose lowering effects. Insulin is necessary for patients with juvenile diabetes or severe adult onset diabetes. Eventually, those diabetic patients develop blindness, kidney failure, and amputation. In the U.S. alone, medical expenses from diabetes complications are over $100 billions annually. Thus, medical expenses from diabetes treatment lead all other medical bills.
About NT Holding Corp.
NT Holding Corp., NT standing for "new technologies," is a publicly- traded holding company looking to merge with or acquire operating business entities through a variety of business combinations. NT will function as an advocate and accelerator for entrepreneurs and scientists, creating a network of people and companies working together to help support and develop new initiatives. These can be in the form of new or emerging growth companies, or new directions, projects, or products within existing structures.
The preceding statements that are not historical facts are based on the Company's current expectations and are subject to the caveat for safe harbor statements appearing below.
Safe Harbor Statements Caveat
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements that are subject to risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw material, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
(1) Time magazine September 4, 2000 page 58 (2) Time magazine December 8, 2003